PUBLISHER: Grand View Research | PRODUCT CODE: 2040382
PUBLISHER: Grand View Research | PRODUCT CODE: 2040382
The global influenza vaccine market size was estimated at USD 8,924.13 million in 2025 and is projected to reach USD 14,797.35 million by 2033, growing at a CAGR of 6.51% from 2026 to 2033. The influenza vaccine sales are expected to increase throughout the forecast period due to an increase in the incidence of seasonal flu and increased recommendations for vaccination against the disease.
According to the WHO, influenza cases have significantly increased as of early 2026, with the US experiencing a severe season, with estimates of over 15 million cases, 180,000 hospitalizations, and 7,400 deaths.According to the CDC's estimates published in October 2023, nearly one billion cases of seasonal influenza are reported globally, including around 3-5 million cases with complications. In addition, a surge in surveillance and government support for vaccination at the country and global levels to monitor vaccine distribution, supply, and administration is one of the growth drivers for the influenza vaccine industry.
The global influenza vaccine industry continues to demonstrate stable and essential growth in the post-pandemic period, supported by sustained awareness of respiratory infectious diseases and the normalization of annual immunization programs. While the surge witnessed during COVID-19 has moderated, vaccination uptake remains higher than pre-pandemic levels in several countries, driven by improved public health awareness and institutional preparedness. According to the CDC, the 2023-2024 influenza season resulted in an estimated 28-35 million illnesses, 310,000-390,000 hospitalizations, and 20,000-25,000 deaths in the U.S., highlighting the continued burden of disease and the critical role of vaccination.
Innovation remains a key growth driver in the influenza vaccine market, particularly with the advancement of next-generation and combination vaccines. Companies are increasingly investing in mRNA-based and recombinant technologies to enhance vaccine efficacy and reduce production timelines. For instance, in October 2023, Moderna, Inc. announced positive Phase 1/2 data for its mRNA-1083 combination vaccine targeting both COVID-19 and influenza, demonstrating a strong immune response against multiple strains. Additionally, Pfizer and BioNTech continued progressing their mRNA-based influenza and combination vaccine candidates into mid-stage clinical trials in 2024.
The market is supported by strong regulatory backing and expanding immunization guidelines globally. Organizations such as the World Health Organization (WHO) continue to update biannual recommendations on strain composition, ensuring vaccine effectiveness against circulating variants. In 2024, the WHO emphasized the inclusion of updated influenza A (H1N1 and H3N2) and influenza B strains in seasonal vaccines. Governments worldwide are also strengthening stockpiling strategies and public vaccination campaigns to mitigate seasonal outbreaks and potential co-infections with other respiratory viruses.
Global Influenza Vaccine Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global influenza vaccine market report based on vaccine type, indication, age group,route of administration, distribution channel, and region: